Ar­Qule’s lead drug tivan­ti­nib flops again in PhI­II liv­er can­cer study

Ar­Qule and Dai­ichi Sankyo’s tivan­ti­nib has come up short in an­oth­er Phase III study.

Five years af­ter the biotech’s lead drug flopped in a late-stage study for non-small cell lung can­cer, in­ves­ti­ga­tors said that the same fate be­fell its Phase III for he­pa­to­cel­lu­lar car­ci­no­ma, a com­mon form of pri­ma­ry liv­er can­cer. The drug flunked the pri­ma­ry end­point on over­all sur­vival.

The drug al­so failed a Phase II in col­orec­tal can­cer in 2013.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.